Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUHAIL H KHADRA

NPI
1487603239
CMS profile
66653
Location
MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$543.76

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $543.76 36

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUHAIL H KHADRA

NPI 1487603239 · CMS profile ID 66653

MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487603239?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487603239?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487603239?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1487603239?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $543.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $13.7012/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747563 CMS
PFIZER INC. $14.9711/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833153921 CMS
Janssen Pharmaceuticals, Inc $13.5010/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303497 CMS
AstraZeneca Pharmaceuticals LP $11.3010/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829904057 CMS
Janssen Pharmaceuticals, Inc $15.7310/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303509 CMS
Novartis Pharmaceuticals Corporation $5.9809/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747561 CMS
Vifor Pharma, Inc. $23.6009/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816129591 CMS
Janssen Pharmaceuticals, Inc $17.4409/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303511 CMS
Novartis Pharmaceuticals Corporation $8.0108/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747559 CMS
Merck Sharp & Dohme Corporation $12.7608/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848460595 CMS
Janssen Pharmaceuticals, Inc $18.7108/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303515 CMS
Novartis Pharmaceuticals Corporation $10.1308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747557 CMS
Novartis Pharmaceuticals Corporation $10.1307/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747555 CMS
Janssen Pharmaceuticals, Inc $20.3407/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303499 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.1107/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768829576 CMS
Vifor Pharma, Inc. $24.3107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816118127 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $18.2207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768829574 CMS
Novartis Pharmaceuticals Corporation $16.3407/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747553 CMS
Novartis Pharmaceuticals Corporation $11.1606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747551 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $20.2106/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768801256 CMS
Janssen Pharmaceuticals, Inc $16.9506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303507 CMS
Janssen Pharmaceuticals, Inc $18.0906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303505 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1905/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763670906 CMS
Janssen Pharmaceuticals, Inc $19.1305/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303513 CMS
Novartis Pharmaceuticals Corporation $6.9004/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747549 CMS
Esperion Therapeutics, Inc. $16.0104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838326891 CMS
Novartis Pharmaceuticals Corporation $13.7504/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747547 CMS
AstraZeneca Pharmaceuticals LP $16.7603/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829881249 CMS
Novartis Pharmaceuticals Corporation $8.2803/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747545 CMS
Janssen Pharmaceuticals, Inc $23.9903/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303503 CMS
Esperion Therapeutics, Inc. $13.7603/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838326887 CMS
Merck Sharp & Dohme Corporation $16.2802/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848320211 CMS
Janssen Pharmaceuticals, Inc $21.0802/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788303501 CMS
Novartis Pharmaceuticals Corporation $12.0402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747543 CMS
Novartis Pharmaceuticals Corporation $12.7701/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812747541 CMS
AstraZeneca Pharmaceuticals LP $11.1301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829875731 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $540.50 20
PY2020 $292.38 14
PY2021 $543.76 36
PY2022 $794.26 44
PY2023 $994.78 34
PY2024 $913.91 39
PY2025 $621.54 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,061,757.66 207
PY2024 Principal investigator $654,195.55 69
PY2023 Principal investigator $594,110.73 53
PY2022 Principal investigator $288,215.55 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,729.61 12/31/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 991134521
Principal investigator 1 Merck Sharp & Dohme LLC $67,725.94 12/31/2023 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1042491817
Principal investigator 1 Merck Sharp & Dohme LLC $12,803.93 12/31/2023 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1042491821
Principal investigator 1 Merck Sharp & Dohme LLC $6,595.72 12/31/2023 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1042491823
Principal investigator 1 PFIZER INC. $9,212.40 12/27/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046146229
Principal investigator 1 Novo Nordisk AS $1,056.94 12/18/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4773 No dispute reported 06/30/2026 1006962267
Principal investigator 1 Janssen Research & Development, LLC $4,752.00 12/15/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113189
Principal investigator 1 Janssen Research & Development, LLC $9,668.00 11/17/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113193
Principal investigator 1 Novo Nordisk AS $810.00 11/10/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007277641
Principal investigator 1 Genentech, Inc. $10,530.00 11/06/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275854
Principal investigator 1 Genentech, Inc. $13,482.00 11/06/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275869
Principal investigator 1 Genentech, Inc. $444.00 11/06/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275883
Principal investigator 1 Genentech, Inc. $2,585.00 11/06/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275897
Principal investigator 1 PFIZER INC. $1,984.50 10/28/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046153223
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,121.00 10/26/2023 Non-covered Recipient Entity
Chicago Medical Research, Llc
Phase IIA 224 HFpEF - A Double-blind, Randomized, Placebo-controlled, Multi-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (H No dispute reported 06/30/2026 1027447223
Principal investigator 1 Janssen Research & Development, LLC $11,174.00 10/25/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113197
Principal investigator 1 Novo Nordisk AS $7,018.88 10/02/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1007567109
Principal investigator 1 Novo Nordisk AS $5,030.10 09/25/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007277631
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 09/22/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113181
Principal investigator 1 Janssen Research & Development, LLC $9,044.00 09/15/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113177
Principal investigator 1 Novo Nordisk AS $2,000.00 08/21/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1007567093
Principal investigator 1 Novo Nordisk AS $1,414.26 08/18/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756571
Principal investigator 1 Janssen Research & Development, LLC $49,853.00 08/16/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113185
Principal investigator 1 PFIZER INC. $3,250.80 08/05/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046225653
Principal investigator 1 Janssen Research & Development, LLC $2,979.00 07/26/2023 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 986113173
Principal investigator 1 Novo Nordisk AS $738.96 07/26/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756547
Principal investigator 1 Novo Nordisk AS $2,368.75 07/26/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756553
Principal investigator 1 Novo Nordisk AS $2,490.00 07/26/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756559
Principal investigator 1 Novo Nordisk AS $3,575.00 07/26/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756565
Principal investigator 1 PFIZER INC. $3,715.20 07/08/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046093757
Principal investigator 1 Genentech, Inc. $3,962.00 07/07/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275841
Principal investigator 1 Novo Nordisk AS $5,884.92 06/23/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756541
Principal investigator 1 Genentech, Inc. $2,712.00 06/02/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275827
Principal investigator 1 Novo Nordisk AS $4,132.08 05/26/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756535
Principal investigator 1 PFIZER INC. $2,404.35 05/25/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046137191
Principal investigator 1 Novo Nordisk AS $20.10 05/12/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756521
Principal investigator 1 Genentech, Inc. $10,757.00 05/10/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1040275813
Principal investigator 1 PFIZER INC. $2,404.35 04/25/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1045995212
Principal investigator 1 Novo Nordisk AS $911.25 04/24/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1007567077
Principal investigator 1 Novo Nordisk AS $4,078.08 04/24/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756527
Principal investigator 1 PFIZER INC. $3,429.00 04/12/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046046353
Principal investigator 1 Novo Nordisk AS $1,822.50 03/24/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1007567063
Principal investigator 1 Novo Nordisk AS $8,686.44 03/24/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1007756515
Principal investigator 1 PFIZER INC. $4,866.75 03/07/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1045963543
Principal investigator 1 Novo Nordisk AS $571.50 02/24/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1007567049
Principal investigator 1 Novo Nordisk AS $3,102.30 02/22/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1009523041
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $187,931.61 02/07/2023 Non-covered Recipient Entity
Chicago Medical Research, Llc
A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP (EMBARK-HFpEF) No dispute reported 06/30/2026 1027447209
Principal investigator 1 PFIZER INC. $1,019.25 02/03/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046093321
Principal investigator 1 AstraZeneca Pharmaceuticals LP $74,834.79 01/25/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 991133229
Principal investigator 1 Novo Nordisk AS $399.37 01/25/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4773 No dispute reported 06/30/2026 1006962257
Principal investigator 1 Novo Nordisk AS $2,507.76 01/25/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1009523025
Principal investigator 1 Novo Nordisk AS $11.64 01/23/2023 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1009523011
Principal investigator 1 PFIZER INC. $5,723.70 01/21/2023 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1046030473